Therefore, it appears that unlike, for example, lung cancer where there is a correlation between specific EGFR mutations and clinical responsiveness to EGFR tyrosine kinase inhibitors[112], in many cases response to rapalogs is not so easy to define based on genotype. This evidence concerns the gene EGFR and lung carcinoma.